June 28, 2021
San Jose, CA (News Direct) June 28, 2021. Rani Therapeutics, a disrupter in oral biologics, today announced the appointment of Laureen DeBuono and Jean Luc Butel to its Board of Directors. Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics designed to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing and has conducted several preclinical and clinical studies to evaluate its safety, tolerability and bioavailability.
Laureen DeBuono, Managing Partner at FLG, is a seasoned financial executive who spent most of her career in long-term, complex Chief Operating Officer and Chief Financial Officer roles at mid and large sized healthcare and consumer-facing companies. Ms. DeBuono has also served as President, Chief Executive Officer, and General Counsel for various private and public companies across multiple sectors. Currently, she is a Managing Partner at FLG Partners, focusing on interim CEO, CFO, and Board advisory services, as well as executive coaching. Additionally, Ms. DeBuono has served on several public company Board of Directors, including Cadence Pharmaceuticals, VISX, and InVivo, and was the Audit Chair at both VISX and InVivo. Ms. DeBuono received her B.A. from Duke University, an M.A. from Stanford University, and a J.D. from New York University School of Law.
Jean-Luc Butel has served as a healthcare executive for more than 30 years and is a well-respected global healthcare advisor. Currently, Mr. Butel serves on various boards at Takeda, Novo Holdings, and SG Innovate, in addition to several healthcare startups in both Asia and Europe. Previously, Mr. Butel served on the board of Varian Medical Systems, the Economic Development Board (EDB) of Singapore, as a senior advisor to McKinsey’s healthcare practice and as an advisor for Singapore’s National Research Foundation. He worked in senior executive positions with Johnson & Johnson, Becton Dickinson, Medtronic and Baxter International. Mr. Butel received his B.A. from The George Washington University and an M.B.A. from the Thunderbird School of International Management.
Full Rani Therapeutics press release is here.